Microbot Medical to Review Recent Progress at HC Wainwright’s 24th Annual Global Investment Conference


Company continues to achieve key goals for its LIBERTY® robotic system in 2022

HINGHAM, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), announced that Harel Gadot, Chairman, President and Chief Executive Officer, will present at HC Wainwright’s 24th Annual Global Investment Conference to be held in New York. Mr. Gadot will provide an overview of the company and recent progress, including the start of the GLP preclinical trial on Tuesday, September 13e at 2:30 p.m. ET.

The presentation will be webcast and accessible through the “Investors” section, under “Presentation + Resources” of the Company’s website at www.microbotmedical.com.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a preclinical medical device company specializing in transformational micro-robotic technologies, primarily focused on the natural and artificial lights of the human body. Microbot’s current proprietary technology platforms form the basis for the development of a Multi-Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Professor Moshe Shoham and Yossi Bornstein with the goal of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. More information about Microbot Medical is available at http://www.microbotmedical.com.

Safe Harbor

Statements regarding future financial and/or operational results, future research growth, technology, clinical development and potential opportunities for Microbot Medical Inc. and its subsidiaries, and other statements regarding expectations, beliefs, goals , future plans or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the federal securities laws. All statements that are not historical facts (including, but not limited to, statements that contain words such as “will”, “believe”, “plan”, “anticipate”, “expect ” and “believes”) should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing products and future technologies, any failure or inability to recruit physicians and clinicians to serve as principal investigators to conduct the early feasibility study of SCS, which could affect or delay this study, uncertainty in preclinical and clinical trial results or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, the need for and ability to raise future capital and maintenance of rights of intellectual property. Additional information about the risks Microbot Medical faces is available under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s website. at www.sec.gov. Microbot Medical disclaims any intention or obligation to update these forward-looking statements, except as required by law.

Investor contacts:

Michel Polyviou
EVC Group
[email protected]

main logo


Comments are closed.